Skip to main content

Advertisement

Figure 3 | Journal of Experimental & Clinical Cancer Research

Figure 3

From: Elevated kinesin family member 26B is a prognostic biomarker and a potential therapeutic target for colorectal cancer

Figure 3

Kaplan-Meier plots with log rank test of overall survival (OS). Overall survival of 88 patients in relation to KIF26B expression levels (A) or Ki67 expression levels (B) determined by immunohistochemical staining of tissue microarrays. OS is significantly lower in patients with tumors expressing high levels of both KIF26B and Ki67 than that in patients with tumors expressing low levels of both KIF26B and Ki67 (C).

Back to article page